PALI
NASDAQPalisade Bio Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks42-80%
2025-12-142026-06-07
Mix2090d
- SEC Filings9(45%)
- Other8(40%)
- Analyst2(10%)
- Earnings1(5%)
Latest news
25 items- PRPalisade Bio to Participate in the Jefferies Global Healthcare ConferenceManagement presentation to take place on Thursday, June 4th at 3:45 PM ET Register for the webcast here Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Jefferies Global Healthcare Conference, being held June 2-4, 2026, in New York, New York. The Company's presentation is scheduled for Thursday, June 4, 2026, at 3:45 PM E
- SECSEC Form EFFECT filed by Palisade Bio Inc.EFFECT - PALISADE BIO, INC. (0001357459) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
- SECSEC Form SCHEDULE 13G filed by Palisade Bio Inc.SCHEDULE 13G - PALISADE BIO, INC. (0001357459) (Subject)
- SECSEC Form S-3 filed by Palisade Bio Inc.S-3 - PALISADE BIO, INC. (0001357459) (Filer)
- SECPalisade Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to support execution through key clinical readouts Denver, CO, May 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead progra
- SECSEC Form 10-Q filed by Palisade Bio Inc.10-Q - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative ColitisData demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval Steady-state pharmacokinetic findings provide mechanistic support for previously reported Phase 1b clinical activity Additional findings support PALI-2108's potential as a once-daily, gut-targeted oral therapy Data presented at Digestive Disease Week 2026 – Access the Poster Here Denver, CO, May 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum a
- SECSEC Form DEFA14A filed by Palisade Bio Inc.DEFA14A - PALISADE BIO, INC. (0001357459) (Filer)
- SECSEC Form DEF 14A filed by Palisade Bio Inc.DEF 14A - PALISADE BIO, INC. (0001357459) (Filer)
- SECSEC Form PRE 14A filed by Palisade Bio Inc.PRE 14A - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that data from its lead program, PALI-2108, has been selected for poster presentation at Digestive Disease Week® (DDW) 2026, taking place May 2–5, 2026 in Chicago. The Company will be in attendance alongside members of its Clinical Advisory Board (CAB), further reinforcing its engagement with leading experts in inflammatory
- ANALYSTWolfe Research initiated coverage on Palisade Bio with a new price targetWolfe Research initiated coverage of Palisade Bio with a rating of Outperform and set a new price target of $7.00
- PRPalisade Bio to Present at the Needham & Co. 25th Annual Healthcare ConferenceVirtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Needham & Co. 25th Annual Healthcare Conference, being held in a virtual format April 14–17, 2026. The Company's virtual presentation is scheduled for Thursday, April 16, 2026, f
- SECPalisade Bio Inc. filed SEC Form 8-K: Other Events8-K - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's DiseasePALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement, with a 47.5% reduction in SES-CD score and 40% of patients achieving endoscopic response and 40% of patients achieving endoscopic remissionPharmacokinetic and pharmacodynamic data from ileal tissue and plasma support once-daily oral dosing for Crohn's disease showing IC90 coverage, with correlation to accepted inflammatory biomarkers Data support expansion into broader luminal CD, an indication that has regulatory clarity, more than doubles the total addressable patient population, and has no a
- ANALYSTH.C. Wainwright initiated coverage on Palisade Bio with a new price targetH.C. Wainwright initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00
- SECSEC Form 10-K filed by Palisade Bio Inc.10-K - PALISADE BIO, INC. (0001357459) (Filer)
- PRPalisade Bio Announces Participation in Two Upcoming Investor ConferencesCarlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows: TD Cowen 46th Annual Health Care ConferenceDate/time: March 2, 2026 at 3:10 PM ESTLocation: Boston Mariott Copley Place, Boston, MAFormat: In-person presentation & investor meetingsWebcast link: Register here Investors registered to attend the conference who wish t
- ANALYSTStifel initiated coverage on Palisade Bio with a new price targetStifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00
- PRPalisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulation Data presented at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, Sweden Carlsbad, CA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmac
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)
PALI FAQ
6 questionsWhat does Palisade Bio Inc. do?
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad...Where does PALI stock trade?
Palisade Bio Inc. (PALI) is listed on NASDAQ.What sector and industry is PALI in?
Palisade Bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about PALI?
Palisade Bio Inc. has had 7 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $700.00 price target on 2026-04-09. Recent price targets range from $500.00 to $2500.00.What companies are similar to PALI?
Notable peers in the same industry include CABA (Cabaletta Bio Inc.), GRPH (Graphite Bio Inc.), ACET (Adicet Bio Inc.), TIL (Instil Bio Inc.), INMB (INmune Bio Inc.). Compare PALI side-by-side with any of them on Quantisnow.How can I track PALI on Quantisnow?
Quantisnow aggregates Palisade Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PALI to receive live email and push alerts on every new disclosure.